# OnCo record nct05482568 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05482568/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05482568", "NCT05482568" ;
  schema:name "A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer"@en ;
  schema:description "A phase 1/2 trial of Adebrelimab, Pyrotinib and Trastuzumab rezetecan in non-small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05482568/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05482568> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-09-15" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/pyrotinib/>, <https://onco.cc/drugs/trastuzumab-rezetecan/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .